KOL thinks Apellis Pharmaceuticals (APLS) issues with Syfovre 'likely solvable' - TD Cowen

Apellis Pharmaceuticals (APLS) extends yesterday's decline, down another 13% on SYFOVRE concerns

July 18, 2023 9:51 AM EDT

(Updated - July 18, 2023 10:24 AM EDT)

Apellis Pharmaceuticals (NASDAQ: APLS) extends yesterday's decline, down another 13%

After the close of trading on Monday, it confirmed reports of six events of retinal vasculitis following SYFOVRE treatment. The issue had weighed on shares during the regular session.

From the filing:

Apellis Pharmaceuticals, Inc. (the Company) has received reports of six events of retinal vasculitis following SYFOVRE® (pegcetacoplan injection) treatment. The Company has... More

Apellis Pharmaceuticals (APLS) call put ratio 1 call to 1 put as shares sell off 33%

July 17, 2023 3:01 PM EDT

Apellis Pharmaceuticals (NASDAQ: APLS) 30-day option implied volatility is at 88; compared to its 52-week range of 38 to 172. Call put ratio 1 call to 1 put as shares sell off 33%.

... More

Apellis Pharmaceuticals (APLS) Halted on Volatility, Down 35%

July 17, 2023 2:47 PM EDT

Apellis Pharmaceuticals (NASDAQ: APLS) Halted on Volatility, Down 35%

... More

Stifel on Apellis Pharmaceuticals (APLS): 'we expect this pressure to be short-lived'

July 17, 2023 1:06 PM EDT

Stifel analyst Annabel Samimy reiterated a Buy rating and $90.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "

The recent ASRS member notification has stoked new safety fears for Syfovre, with notification of six IOI events with retinal vasculitis, calculated... More

Increasing unusual call option volume: LU GSAT BBIO OPRA FNGR EVGO APLS

July 17, 2023 10:32 AM EDT

Increasing unusual call option volume: LU GSAT BBIO OPRA FNGR EVGO APLS

... More

Citi Keeps Buy Rating on Apellis Pharmaceuticals (APLS), Comments on Premarket Selloff

July 17, 2023 9:11 AM EDT

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $106.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)

The analyst comments "The stock is down substantially this AM following an ASRS member notification yesterday regarding a small number of events of intraocular inflammation (IOI, exact number... More

Evercore ISI Remains Positive on Apellis Pharmaceuticals (APLS)

July 17, 2023 9:08 AM EDT

Evercore ISI analyst Umer Raffat reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "Facts: 6 cases of occlusive retinal vasculitis. 7-13 days post-drug. Outcomes evolving. - APLS mentions that there is not consensus on 6 cases (KOLs on our call agree). This ASRS update is NOT peer-reviewed - Also, 1/6 patient has significant vision loss outcomes on other may not be as significant But regardless, one thing is clear: such cases had not been in clinical trials previously. Perhaps thats the first distinction vs Novartis Beovu: There were cases of retinal artery... More

Apellis Pharmaceuticals (APLS) plunges as occlusive retinal vasculitis observed from Syfovre launch

July 17, 2023 7:11 AM EDT

Apellis Pharmaceuticals (NASDAQ: APLS) witnessed a dramatic decline of approximately 40% in pre-market trading on Monday. This decline followed the distribution of a notification by the ASRS Research and Safety in Therapeutics (ReST) Committee to its members over the weekend. The notification provided key information including the observation of six cases of occlusive retinal vasculitis since the launch of Syfovre, according to Raymond James analysts. Importantly, all these events occurred after the first injection, within a time frame of 7 to 13 days post-injection, with no specific product lots implicated. Meanwhile, over... More

Apellis Pharmaceuticals (APLS) PT Raised to $115 at Baird, 'Survey data bode well for the ongoing launch of Syfovre'

July 17, 2023 6:53 AM EDT

Baird analyst Colleen Kusy raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $115.00 (from $105.00) while maintaining a Outperform rating.

The analyst comments "Survey data bode well for the ongoing launch of Syfovre, raising price target. In early July, we conducted a survey of... More

Raymond James Comments on Apellis Pharmaceuticals (APLS) Amid Stock Selloff in Premarket

July 17, 2023 5:54 AM EDT

Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "The ASRS Research and Safety in Therapeutics (ReST) Committee distributed a notification to its members on Saturday (7/15) indicating 1) 6 cases of occlusive retinal vasculitis have been observed since Syfovre launch, 2) all events observed after 1st injection, between 7-13 days post injection, 3) no specific product lots implicated. Moreover, the communication indicates ~60,000 vials of Syfovre have been distributed since FDA approval. We spoke with Apellis who confirmed the details. We highlight relevant occlusive retinal... More